Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats

Synapse

Volumn 36, Issue 4, 2000, Pages 267-274

  Marin, Concepció ^a,c   Jimenez, Anna ^a   Bonastre, Mercè ^a   Chase, Thomas N ^b   Tolosa, Eduardo ^a  

^a Inst d'Investigations B   (Spain)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Glutamate antagonists; Levodopa; Motor fluctuations; Parkinsonism; Rotation

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RILUZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG RECEPTOR BINDING; MALE; MOTOR PERFORMANCE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; DEXTROMETHORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; LEVODOPA; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PIPERAZINES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RILUZOLE; ROTATION;

EID: 0034659603     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000615)36:4<267::AID-SYN3>3.0.CO;2-Y     Document Type: Article

References (44)

1. Albin RL, Makowiec RL, Hollingsworth ZR, Dure LS IV, Penny JB, Young AB. 1992. Excitatory amino acid binding sites in the basal ganglia of the rat: quantitative autoradiographic study. Neuroscience 46:135-148.
2. Aram JA, Martin D, Tomczyk M, Zemaan S, Millar J, Pohler G, Lodge D. 1989. Neocortical epileptogenesis in vitro: studies with N-methyl-D-aspartate, phecyclidine, sigma and dextromethrophan receptor ligands. J Pharmacol Exp Ther 248:320-328.
3. Barbeito L, Chéramy A, Godeheu G, Desce JM, Glowinski J. 1990. Glutamate receptors of a quisquilate-kainate subtype are involved in the presynaptic regulation of dopamine release in the caudate nucleus in vivo. Eur J Neurosci 2:304-311.
4. Bernard V, Gardiol A, Faucheux B, Bloch B, Agid Y, Hirsch E. 1996. Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion. J Comp Neurol 368:553-568.
5. Bernard V, Somogoyi P, Bolam JP. 1997. Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. J Neurosci 17:819-833.
6. Blanchet PJ, Verhagen Metman L, Mouradian M, Chase TN. 1996. Acute pharmacological blockade of dyskinesias in Parkinson's disease. Mov Disord 11:580-581.
7. Blanchet PJ, Papa SM, Metman LV, Mouradian, MM. Chase TN. 1997. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev 21:447-453.
8. Blanchet PJ, Konisiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN. 1998. NR1A/2B selective NMDA antagonists inhibit levodopa-induced dyskinesias in MPTP monkeys. Neurosci Abstr 24:1721.
9. Calabresi P, Pisani A, Centonze D, Bernardi G. 1997. Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci Biobehav Res 21:519-523.
10. Carpenter CL, Marks SS, Watson DL, Greenberg DA. 1988. Dextromethorphan an dextrorphan as calcium channel antagonists. Brain Res 439:332-335.
11. Chase TN. 1998. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50(Suppl. 5):S17-S25.
12. Chase TN, Oh JD, Blanchet PJ. 1998. Neostriatal mechanisms in Parkinson's disease. Neurology 51:S30-S35.
13. Chéramy A, Barbeito L, Godeheu G. Glowinski J. 1992. Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147:209-212.
14. Choi DW. 1987. Dextrophan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 403:333-336.
15. Dev KK, Petersen V, Honore T, Henley JM. 1996. Pharmacology and regional distribution of the binding of 6-[3H]nitro-7-sulphamoyl-benzo[f]-quinoxaline-2,3,-dione to rat brain. J Neurochem 67:2609-2612.
16. Engber TM, Papa SM, Boldry RC, Chase TN. 1994. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5:2586-2588.
17. Fenu S, Carta A, Morelli M. 1995. Intranigral injections of glutamate antagonists modulate dopamine D-1 mediate turning behavior and striatal c-fos expression. J Neural Transm 45:75-81.
18. Gossel M, Schmidt WJ, Loscher W, Zajaczkowski W, Danysz W. 1995. Effect of coadministration of glutamate receptor antagonists and dopaminergic agonists in locomotion in monoamine-depleted rats. J Neural Transm (PD Sect) 10:27-39.
19. Healy DJ, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ, Meador-Woodruff JH. 1998. AMPA receptor binding subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology 19:278-286.
20. Hurtig HI. 1997. Problems with current pharmacologic treatment of Parkinson's disease. Exp Neurol 144:10-16.
21. Kaur S, Starr MS. 1995. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur J Pharmacol 280:159-166.
22. Klockgether T, Turski L. 1990. NMDA antagonists potentiate anti-parkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 28:539-546.
23. Klockgether T, Turski L, Honoré T, Zhang Z, Gash DM, Kurlan R, Greenamyre JT. 1991. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 30:717-723.
24. Konisiotis S, Blanchet PJ, Whittemore ER, Woodwars RM, Chase TN. 1998. The effect of different NMDA antagonists on levodopa-induced dyskinesias in parkinsonian monkeys. Neurosci Abstr 24: 1721.
25. Kotter R. 1994. Postsynaptic iteration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 44:163-196.
26. Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jahnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD. 1991. Synergism of the AMPA-antagonist NBQX and the NMDA antagonist CPP with L-dopa in models of Parkinson's disease. J Neural Transm 3:203-213.
27. Löschmann PA, Wullner U, Heneka MT, Schulz JB, Kunow M, Wachel H, Klockgether T. 1997. Differential interaction of competitive NMDA AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse 26:381-391.
28. Luquin MR, Obeso JA, Laguna J, Guillen J, Martinez Lage JM. 1993. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Eur J Pharmacol 235:297-300.
29. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. 1996. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 736:202-205.
30. Marsden CD, Parkes JD. 1977. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 8007:345-349.
31. Menegoz M, Lau LF, Here D, Huganir RL, Girault JA. 1995. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 7:125-128.
32. Oh JD, Del Otto P, Chase TN. 1997. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemiparkinsonian rat. Neurosci Lett 228:5-8.
33. Oh JD, Russell D, Vaughan CL, Chase TN. 1998. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits; effect of dopaminergic denervation and levodopa administration. Brain Res 813:150-159.
34. Papa SM, Chase TN. 1996. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 39:574-578.
35. Papa SM, Engber TM, Chase TN. 1994. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69-74.
36. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. 1995. Reversal of levodopa induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 701:13-18.
37. Paxinos G, Watson C. 1982. The rat brain in stereotaxic coordinates. New York: Academic Press.
38. Schultz W. 1994. Behavior-related activity of primate dopamine neurons. Rev Neurol 150:634-639.
39. Slusher BS, Rissolo KC, Anzilotti KF, Jackson PF. 1995. Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats. J Neural Transm 9:145-159.
40. Starr M. 1995. Glutamate/Dopamine D1/D-2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19:264-293.
41. Starr MS, Starr BS, Kaur S. 1997. Stimulation of basal and L-dopa-induced motor response activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci Biobehav Rev 21:437-446.
42. Tingley WG, Ehler MD, Kameyana K, Doherty C, Ptak JB, Riley CT, Huganir RL. 1997. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit phosphorylation site-specific antibodies. J Biol Chem 272:5157-5166.
43. Verhagen Metman L, Del Dotto P, Natte R, van der Munckhof P, Chase TN. 1998a. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 51:203-206.
44. Verhagen Metman L, Del Dotto P, Van der Munckhof P, Fang J, Mouradian MM, Chase TN. 1998b. Amantadine as treatment for dyskinesias motor fluctuations in Parkinson's disease. Neurology 50:1323-1326.